David J Cote
Overview
Explore the profile of David J Cote including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
118
Citations
1792
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cheok S, Ruzevick J, Briggs R, Cote D, Shah I, Gomez D, et al.
J Neurosurg
. 2025 Mar;
:1-9.
PMID: 40085941
Objective: Pituitary adenomas (PAs) are common lesions that often present with endocrinopathy and/or visual symptoms. Classification of PAs has historically been based on functional status and histopathological staining of anterior...
2.
Shah I, Chung R, Gomez D, Cote D, Briggs R, Zada G
World Neurosurg
. 2025 Feb;
197:123831.
PMID: 39987977
No abstract available.
3.
Raub S, Fixman B, Thomas H, Hanks T, Dominic N, Nistal D, et al.
World Neurosurg
. 2025 Feb;
:123791.
PMID: 39952399
Background: Accurate lineage identification of pituitary neuroendocrine tumors (PitNETs) is critical to inform our understanding of tumor biology and aggressiveness. While this was previously performed using immunohistochemistry for anterior pituitary...
4.
Pham J, Cote D, Kang K, Briggs R, Gomez D, Prasad A, et al.
J Neurooncol
. 2025 Feb;
PMID: 39907975
Purpose: Methylation of the O-methylguanine-DNA methyltransferase (MGMT) promoter is an important prognostic marker in glioblastoma (GBM); however, its implementation in clinical practice remains understudied. Here, we assessed the prevalence of...
5.
Guerra G, Kashif Z, Cote D, Feng J, Renn A, Yang M, et al.
J Neurosurg
. 2025 Jan;
1-8.
PMID: 39854708
Objective: The present study aimed to investigate the association between pituitary adenoma (PA) consistency and other measurable tumor characteristics, extent of resection (EOR), postoperative complications, and outcomes. Methods: In total,...
6.
Shah I, Chung R, Liu K, Cote D, Briggs R, Guerra G, et al.
J Neurosurg
. 2025 Jan;
1-7.
PMID: 39793013
Objective: Tumor consistency, or fibrosity, affects the ability to optimally resect meningiomas, especially with recent trends evolving toward minimally invasive approaches. The authors' team previously validated a practical 5-point scale...
7.
Nawabi N, Emedom-Nnamdi P, Kilgallon J, Gerstl J, Cote D, Jha R, et al.
Neurosurgery
. 2024 Jun;
96(1):183-192.
PMID: 38912791
Background And Objectives: Digital phenotyping (DP) enables objective measurements of patient behavior and may be a useful tool in assessments of quality-of-life and functional status in neuro-oncology patients. We aimed...
8.
Gomez D, Feng J, Cheok S, Shah I, Dicharry H, Cote D, et al.
J Neurooncol
. 2024 Jun;
169(3):457-467.
PMID: 38896356
Purpose: A systematic review was conducted to investigate differences in incidence and primary origin of synchronous brain metastasis (sBM) in varying racial groups with different primary cancers. Methods: Adhering to...
9.
Cote D, Peterson R, Zada G
Oper Neurosurg (Hagerstown)
. 2023 Nov;
26(2):245.
PMID: 37976144
No abstract available.
10.
Bove I, Cheok S, Feng J, Briggs R, Ruzevick J, Cote D, et al.
World Neurosurg
. 2023 Nov;
182:e62-e66.
PMID: 37967742
Objective: According to the 2017 World Health Organization classification of neuro-endocrine tumors, pituitary adenomas (PAs) are classified according to immunoexpression of the pituitary-specific transcription factors (TFs). A small subset of...